KR840001170A - 신규 유기아마이드 화합물의 제법 - Google Patents
신규 유기아마이드 화합물의 제법 Download PDFInfo
- Publication number
- KR840001170A KR840001170A KR1019820003484A KR820003484A KR840001170A KR 840001170 A KR840001170 A KR 840001170A KR 1019820003484 A KR1019820003484 A KR 1019820003484A KR 820003484 A KR820003484 A KR 820003484A KR 840001170 A KR840001170 A KR 840001170A
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- nitrogen
- carboxylic acid
- saturated
- residue
- Prior art date
Links
- -1 Organic Amide Compounds Chemical class 0.000 title claims 7
- 238000002360 preparation method Methods 0.000 title claims 3
- 239000002253 acid Substances 0.000 claims 55
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 36
- 239000011521 glass Substances 0.000 claims 27
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 26
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 18
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 17
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 16
- 150000002632 lipids Chemical class 0.000 claims 14
- HZNQSWJZTWOTKM-UHFFFAOYSA-N 2,3,4-trimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1OC HZNQSWJZTWOTKM-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229960003512 nicotinic acid Drugs 0.000 claims 9
- 235000001968 nicotinic acid Nutrition 0.000 claims 9
- 239000011664 nicotinic acid Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 8
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims 8
- 229930195729 fatty acid Natural products 0.000 claims 8
- 239000000194 fatty acid Substances 0.000 claims 8
- 150000004665 fatty acids Chemical class 0.000 claims 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 claims 6
- 229950003769 acefylline Drugs 0.000 claims 6
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 6
- 229960000604 valproic acid Drugs 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- 235000021355 Stearic acid Nutrition 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 3
- 125000006239 protecting group Chemical group 0.000 claims 3
- 235000003441 saturated fatty acids Nutrition 0.000 claims 3
- 239000008117 stearic acid Substances 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 2
- 235000021314 Palmitic acid Nutrition 0.000 claims 2
- VAKIESMDOCVMDV-HNNXBMFYSA-N Spinosine Chemical compound C1C2=CC(O)=C(O)C=C2C[C@@H]2N1CCC1=C2C=C(OC)C(OC)=C1 VAKIESMDOCVMDV-HNNXBMFYSA-N 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- 150000001718 carbodiimides Chemical class 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 150000003841 chloride salts Chemical class 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 235000020778 linoleic acid Nutrition 0.000 claims 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 2
- 235000021313 oleic acid Nutrition 0.000 claims 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical group OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960004488 linolenic acid Drugs 0.000 claims 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DUZPCMXUYQIWCZ-UHFFFAOYSA-N n'-(3-phenylpropyl)methanediimine Chemical compound N=C=NCCCC1=CC=CC=C1 DUZPCMXUYQIWCZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000627 niacin group Chemical group 0.000 claims 1
- 150000002989 phenols Chemical class 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 229950004354 phosphorylcholine Drugs 0.000 claims 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 claims 1
- 229940081066 picolinic acid Drugs 0.000 claims 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (51)
- 다음 일반식(Ⅰ)의 유기 아마이드 화합물 또는 약리학상 허용되는 염류.위 식에서 R-CO는 카르복실산의 잔기로서 단, 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연 지방산이 아니고 R2는 수소원자, 포화된 C1-7알칼기 또는 포화된 C4-7사이클로알킬기이며, R3N는 질소함유 리피드의 잔기이다.
- 1항에 있어서, 카르복실기가 리서직산, 이소리서직산, 디하이드로리서직산, 2-브로모리서직산, 2-브로모-디하이드로리서직산, 1-메틸레서직산, 1-메틸-디하이드로리서직산, 1-메틸-2-브로모-리서직산, 1-메틸-2-브로모-디하이드로리서직산, 감마-아미노부티릭산, 발프로익산, 트리메톡시벤조익산, 니코틴산, 이소니코틴산, 피크린산 및 테오필린초산으로부터 선택된 것임을 특징으로 하는 화합물.
- 1항에 있어서 R2가 수소원자를 나타냄을 특징으로 하는 화합물.
- 1항 또는 2항에 있어서 질소함유리피드가 포스포리피드임을 특징으로 하는 화합물.
- 1항 또는 2항에있어서 질소함유리피드가 스핀고리피드임을 특징으로 하는 화합물.
- 4항에 있어서 포스포리피드가 포스파티딜에 탄올아민 또는 포스파티딜세린임을 특징으로 하는 화합물.
- 5항에 있어서 스핀고리피드가 유리아민(NH2)기 및 탄소원자수 12-22개의 스핀고신 잔기를 가진 스핀고리피드임을 특징으로 하는 화합물.
- 5항에 있어서 스핀고리피드가 스핀고신, 디하이드로스핀고신, 프시코신, 디하이드로시프코신, 스핀고신포스포릴콜린, 디하이드로스핀고신포스포릴콜린 및 피토스핀고신으로부터 선택된 것임을 특징으로 하는 화합물.
- 1항에 있어서, R2가 수소이고, 리피드가 스핀고신이며, 카르복실산이 감마-아미노부티릭산, 리서직산, 이소리서직산, 디하이드로리서직산, 발프로익산, 트리메톡시벤조익산, 테오필린초산, 니코틴산 및 이소니코틴산으로부터 선택된 것임을 특징으로 하는 화합물.
- 1항에 있어서 R2가 수소이고, 리피드가 트리메톡시벤조익산, 니코틴산, 디하이드로리서직산, 리서직산 및 이소리서직산으로부터 선택된 것임을 특징으로하는 화합물.
- 1항에 있어서 R2가 수소이고 리피드가 스핀고신포스포릴콜린이며, 카르복실산이 트리메톡시벤조익산임을 특징으로 하는 화합물.
- 1항에 있어서 R2가 수소이고, 리피드가 디하이드로스핀고신이며, 카르복실산이 디하이드로리서직산임을 특징으로 하는 화합물.
- 1항에 있어서 다음 일반식을 가진 트리메톡시벤조일포스파티딜세린 아마이드류임을 특징으로 하는 화합물위 식에서 R 및 R'는 포화 또는 불포화지방산류이다.
- 1항에 있어서 다음 일반식을 가진 니코티닐포스파티딜세린 아마이드류임을 특징으로 하는 화합물.위 식에서 R 및 R'는 포화 또는 불포화 지방산류이다.
- 13항 또는 14항에 있어서 R'가 스테아린산, 팔미틴산, 올레인산, 리놀레닉산, 리놀레인산 및 아라키도닉산으로부터 선택된 것임을 특징으로 하는 화합물.
- 1항에 있어서 다음 일반식을 가진 트리메톡시벤조일포스파티딜세린 아마이드류임을 특징으로 하는 화합물.위 식에서, R는 포화 또는 불포화 지방산류이다.
- 16항에 있어서 R가 스테아린산 또는 올레인산임을 특징으로 하는 화합물.
- 1항에 있어서 다음 일반식을 가진 트레메톡시벤조일포스파티딜에탄올아민 아마이드류임을 특징으로 하는 화합물.위 식에서, R 및 R'는 포화 또는 불포화 지방산이다.
- 18항에 있어서 R 및 R'가 올레인산, 스테아린산, 팔미틴산, 리놀레인산 및 아라키도닉산으로부터 선택된 것임을 특징으로 하는 화합물.
- 유효성분으로서 다음 일반식(Ⅰ)의 유기 아마이드 회합물 또는 약리학상 허용되는 염류와 약리학상 허용되는 담체 또는 희석제를 함유한 약제조성물.위 식에서, R1-CO는 카르복실산의 잔기로서 단 카르복실산은 질소함유 리피드의 질소에 정상적으로 결합된 천연 지방산이 아니고, R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 질소함유리피드의 잔기이다.
- 20항에 있어서 카르복실산이 리서직산, 이소리서직산, 디하이드로리서직산, 2-브로모-리서직산, 3-브로모-디하이드로리서직산, 1-메틸-리서직산, 1-메틸-디하이드로리서직산, 1-메틸-2-브로모-리서직산, 1-메틸-2-브로모-디하이드로리서직산, 감마-아미노부티릭산, 발프로익산, 트리메톡시벤조익산, 니코틴산, 이소니코틴산, 피콜린산 및 테오필린초산으로부터 선택된 것임을 특징으로 하는 약제조성물.
- 20항에 있어서 R2가 수소원자임을 특징으로 하는 약제 조성물.
- 20항에 있어서 질소함유리피드가 포스포리피드임을 특징으로 하는 약제조성물.
- 20항에 있어서 질소함유리피드가 스핀고리피드임을 특징으로 하는 약제조성물.
- 23항에 있어서 포스포리피드가 포스파티딜에탄올아민 또는 포스파티딜세린임을 특징으로 하는 약제조성물.
- 24항에 있어서 스핀고리피드가 유리아민(NH2)기와 탄소원자수 12-22개의 스핀고신 잔기를 가진 스핀고리피드임을 특징으로 하는 약제조성물.
- 20항에 있어서 스핀고리피드가 스핀고신, 디하이드로스핀고신, 프시코신, 디하이드로프시코신, 스핀고신포스포릴콜린, 디하이드로스핀고신, 포스포릴콜린 및 피토스핀고신으로부터 선택된 것임을 특징으로 하는 약제조성물.
- 20항에 있어서 R2가 수소이고, 리피드가 스핀고신이며, 카르복실산이 감마-아미노부티릭산, 리서직산, 이소리서직산, 디하이드로리서직산, 발프로익산, 트리메톡시벤조익산, 테오필린초산, 니코틴산 및 이소니코틴산으로부터 선택된 것임을 특징으로 하는 약제조성물.
- 20항에 있어서 R2가 수소이고, 리피드가 프시코신이며, 카르복실산이 트리메톡시벤조익산, 니코틴산, 디하이드로리서직산, 리서직산 및 이소리서직산으로부터 선택된 것임을 특징으로 하는 약제조성물.
- 20항에 있어서 R2가 수소이고, 리피드가 스핀고신포스포릴콜린이며, 카르복실산이 트리메톡시벤조익산임을 특징으로 하는 약제조성물.
- 20항에 있어서 R2가 수소이고, 리피드가 디하이드로스핀고신이며, 카르복실산이 디하이드로리서직산임을 특징으로 하는 조성물.
- 일반식 R1COOH의 카르복실산을 페놀과 반응시켜 에스텔을 형성하고, 이 에스텔을 질소함유리피드와 반응시킴을 특징으로 하는 다음 일반식(Ⅰ)의 유기아마이드 화합물 및 약리학상 허용되는 염류를 제조하는 방법.위 식에서 R1-CO는 카르복실산의 잔기로서 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연지방산이 아니고, R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 질소함유리피드의 잔기이다.
- 32항에 있어서 상술한 페놀이 파라-니트로페놀임을 특징으로 하는 방법.
- 일반식 R1COOH의 카르복실산을 트리플루오로초산과 반응시켜 혼합 무수물을 형성하고, 이 혼합무수물을 질소함유리피드와 반응시킴을 특징으로 하는 다음 일반식(Ⅰ)이 유기아마이드 화합물 및 약리학상 허용되는 염류의 제조방법.위 식에서, R1-CO는 카르복실산의 잔기로서 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연지방산이 아니고 R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 질소함유리피드의 잔기이다.
- 일반식 R1-COOH의 카르복실산을 카르보디이미드 및 1-하이드록시벤조트리아졸로부터 선택된 적어도 하나의 존재하에 질소함유리피드와 반응시킴을 특징으로 하는 다음 일반식(Ⅰ)의 유기아마이드 화합물 및 약리학상 허용되는 염류 제조방법.위 식에서, R1-CO는 카르복실산의 잔기로서 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연지방산이 아니고 R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 질소함유리피드의 잔기이다.
- 35항에 있어서 카르보디이미드가 디사이클로헥실카르보디이미드 벤질이소프로필카르보디이미드 또는 벤젤에틸카르보디이미드임을 특징으로 하는 방법.
- 일반식 R1-COOH의 카르복실산의 클로라이드를 제조하고, 이 클로라이드를 질소함유리피드와 반응시킴을 특징으로 하는 다음 일반식(Ⅰ)이 유기 아마이드화합물 약리학상 허용되는 염류의 제조방법.위 식에서, R1-CO는 카르복실산의 잔기로서 카르복실산은 리피드의 질소에 정상적으로 결합된 천연지방산이 아니고, R2는 수소원자 또는 포화된 C1-7알킬기 또는 포화된 C4-7사이클로 알킬기이며, R3는 질소함유리피드의 잔기이다.
- 일반식 R1-COOH의 카르복실산을 N,N'-카르보닐이미다졸과 반응시켜 아실이미다졸을 형성하고, 이 아실이미다졸을 질소함유리피드와 반응시킴을 특징으로 하는 다음 일반식(Ⅰ)의 유기아마이드 화합물 및 약리학상 허용되는 염류의 제조방법.위 식에서 R1-CO는 카르복실산의 잔기로서 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연지방산이 아니고, R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 질소함유리피드의 잔기이다.
- 감마-아미노부티릭산과 보호기를 반응시켜 아미노기를 보호하고, 보호된 감마-아미노부티릭산을 특허청구범위 32-38항중 어느 하나에 따라 질소함유리피드와 반응시킨후 보호기를 제거함을 특징으로 하는 다음 일반식(Ⅰ)의 유기아마이드 화합물 및 약리학상 허용되는 염류의 제조방법.위 식에서, R1-CO는 카르복실산의 잔기로서 단, 카르복실산은 질소함유리피드의 질소에 정상적으로 결합된 천연지방산이 아니고, R2는 수소원자 포화된 C1-7알킬기 또는 포화된 C4-7사이클로알킬기이며, R3-N는 , 소함유리피드의 잔기이다.
- 39항에 있어서 보호기가 프탈로일 또는 벤질옥시카르보닐임을 특징으로 하는 방법.
- 질소함유리피드로서 카르복실산의 아마이드를 제조하여 다음 일반식(Ⅰ)의 화합물 및 약리학상 허용되는 염류를 형성함을 특징으로 하는 시험관내 생리적 활성을 가진 카르복실산의 생체내 생리작용을 증강시키는 방법.위 식에서 R1-CO는 카르복실산의 잔기이며, R2는 수소원자, 포화된 C1-7알킬기 또는 포화된 C4-7싸이클로알킬기이며, R3-7은 질소함유리피드의 잔기이다.
- 41항에서 카르복실산이 리서직산, 이소리서직산, 디하이드로리서직산, 2-브로모-리서직산, 2-브로모-디하이드로리서직산, 1-메틸리서직산, 1-메틸-디하이드로리서직산, 1-메틸-2-브로모-리서직산, 1-메틸-2-브로모-디하이드로리서직산, 감마-아미노부티릭산, 발프로익산, 트리메톡시벤조익산, 니코틴산, 이소티코틴산, 피콜린산 및 테오필린초산으로부터 선택된 것임을 특징으로 하는 방법.
- 41항에 있어서 R2가 수소원자임을 특징으로 하는 방법.
- 41 또는 42항에 있어서 질소함유리피드가 포스포리피드임을 특징으로 하는 방법.
- 41항 또는 42항에 있어서 질소함유리피드가 스핀고리피드임을 특징으로 하는 방법.
- 44항에 있어서 포스포리피드가 포스파티딜에탄올 아민 또는 포스파티딜세린임을 특징으로 하는 방법.
- 45항에 있어서 스핀고리피드가 스핀고신, 디하이드로스핀고신, 프시코신, 디하이드로프시코신, 스핀고신포스포릴콜린, 디하이드로스핀고신포스포릴콜린 및 피토스핀고신으로부터 선택된 것임을 특징으로 하는 방법.
- 41항에 있어서 R2가 수소이고, 리피드가 스핀고신이며, 카르복실산이 감마-아미노부티릭산, 리서직산, 이소리서직산, 디하이드로리서직산, 발프로익산, 트리메톡시벤조인산, 테오필린초산, 니코틴산 및 이소니코틴산으로부터 선택된 것임을 특징으로 하는 방법.
- 41항에 있어서 R2가 수소이고, 리피드가 프시코신이며, 카르복실산이 트리메톡시벤조인산, 니코틴산, 디하이드로리서직산, 리서직산 및 이소리서직산으로부터 선택된 것임을 특징으로 하는 방법.
- 41항에 있어서 R2가 수소이고, 리피드가 스핀고신포스포릴콜린이며, 카르복실산이 트리메톡시벤조인산임을 특징으로 하는 방법.
- 42항에 있어서 R2가 수소이고, 리피드가 디하에드로스핀고신이고, 카르복실산이 디하이드로리서직산임을 특징으로 하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT49031/81A IT1171432B (it) | 1981-08-03 | 1981-08-03 | Amidi organiche derivate da lipidi azotati utilizzabili come farmaci |
IT49031-A/81 | 1981-08-03 | ||
IT49031A/81 | 1981-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR840001170A true KR840001170A (ko) | 1984-03-28 |
KR880000042B1 KR880000042B1 (ko) | 1988-02-20 |
Family
ID=11269438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR8203484A KR880000042B1 (ko) | 1981-08-03 | 1982-08-03 | 신규 유기 아마이드 화합물의 제법 |
Country Status (21)
Country | Link |
---|---|
US (3) | US4757053A (ko) |
EP (1) | EP0072286B2 (ko) |
JP (2) | JPS5843942A (ko) |
KR (1) | KR880000042B1 (ko) |
AT (1) | ATE23165T1 (ko) |
AU (1) | AU561811B2 (ko) |
DE (1) | DE3273983D1 (ko) |
DK (1) | DK159204C (ko) |
ES (3) | ES8501735A1 (ko) |
FI (1) | FI75829C (ko) |
GR (1) | GR76234B (ko) |
HU (1) | HU192771B (ko) |
IE (1) | IE53644B1 (ko) |
IL (1) | IL66454A0 (ko) |
IT (1) | IT1171432B (ko) |
NO (1) | NO161314C (ko) |
NZ (1) | NZ201439A (ko) |
PL (1) | PL141417B1 (ko) |
PT (1) | PT75363B (ko) |
YU (3) | YU43085B (ko) |
ZA (1) | ZA825585B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496566B1 (ko) * | 2002-06-11 | 2005-06-23 | 주식회사 포스코 | 탈황능이 향상된 무연탄을 이용한 용선용 탈황제 |
US20190289401A1 (en) * | 2018-03-15 | 2019-09-19 | Onkyo Corporation | Diaphragm, speaker unit using same, headphone and earphone, and diaphragm manufacturing method |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1171432B (it) * | 1981-08-03 | 1987-06-10 | Fidia Farmaceutici | Amidi organiche derivate da lipidi azotati utilizzabili come farmaci |
US5189017A (en) * | 1982-07-23 | 1993-02-23 | Ciba-Geigy Corporation | Use of sugar derivatives for the prophylaxis and treatment of virus infections |
US5334583A (en) * | 1982-07-23 | 1994-08-02 | Ciba-Geigy Corp. | Use of sugar derivatives for the prophylaxis and treatment of virus infections |
DE3572491D1 (en) * | 1984-07-25 | 1989-09-28 | Ciba Geigy Ag | Phosphatidyl compounds, process for their preparation and their use |
US4885285A (en) * | 1984-09-13 | 1989-12-05 | Ciba-Geigy Corporation | Phosphorus compounds, processes for their manufacture, and their use |
LU85971A1 (fr) * | 1985-06-25 | 1987-01-13 | Oreal | Nouveaux composes lipidiques amphiphiles, leur procede de preparation et leurs applications,notamnent en cosmetique et en dermopharmacie |
US4873322A (en) * | 1986-01-24 | 1989-10-10 | Ciba-Geigy Corporation | Saccharide derivatives and processes for their manufacture |
US5434190A (en) * | 1986-08-08 | 1995-07-18 | Colgate-Palmolive Co. | N-aryl and N-cycloalkyl neoalkanamide insect repellents |
EP0299201A3 (de) * | 1987-06-12 | 1990-08-22 | Wilhelm Dr. Hoerrmann | Fett-Aminoalkohol enthaltendes Arzneimittel |
US5534553A (en) * | 1987-06-12 | 1996-07-09 | Hoerrmann; Wilhelm | Drug containing fatty amino alcohols or derivatives thereof |
DE3819870A1 (de) * | 1987-06-12 | 1988-12-29 | Hoerrmann Wilhelm | Arzneimittel auf der basis von fett-amino-alkoholen |
JP2588729B2 (ja) * | 1987-10-05 | 1997-03-12 | 塩野義製薬株式会社 | スフィンゴシン誘導体 |
IT1235162B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisosfingolipidi |
IT1238346B (it) * | 1989-11-14 | 1993-07-13 | Gangliosidi modificati e loro derivati funzionali. | |
US6362003B1 (en) | 1992-02-24 | 2002-03-26 | Coulter Corporation | Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof |
US6509192B1 (en) * | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
DE4229877C2 (de) * | 1992-09-04 | 1994-09-15 | Max Delbrueck Centrum | Phospho- bzw. Phosphono-(N-acyl)-serine und ihre Herstellung |
US5346914A (en) * | 1993-05-14 | 1994-09-13 | Abbott Laboratories | (4-alkoxypyran-4-yl) substituted arylalkylaryl-, arylalkenylaryl-, and arylalkynylarylurea inhibitors of 5-lipoxygenase |
US5635536A (en) * | 1994-12-07 | 1997-06-03 | Pharmacia & Upjohn Aktiebolag | Emulsion suitable for administering a sphingolipid |
US6092636A (en) * | 1997-08-07 | 2000-07-25 | Nsk-Warner K.K. | Oneway clutch |
JP3874215B2 (ja) * | 1997-08-07 | 2007-01-31 | Nskワーナー株式会社 | ワンウェイクラッチおよびワンウェイクラッチ用外輪・ 保持器組立体 |
US6756504B2 (en) | 2000-04-19 | 2004-06-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
AU2001252506A1 (en) * | 2000-04-19 | 2001-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids |
US7217696B2 (en) | 2002-02-28 | 2007-05-15 | A & D Bioscience, Inc. | Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof |
WO2003079980A2 (en) * | 2002-03-19 | 2003-10-02 | A & D Bioscience, Inc. | Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof |
US20050255038A1 (en) * | 2002-04-12 | 2005-11-17 | A And D Bioscience, Inc. | Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof |
JP4459629B2 (ja) | 2002-04-12 | 2010-04-28 | メルク エンド カムパニー インコーポレーテッド | 二環式アミド |
FR2839310A1 (fr) * | 2002-05-03 | 2003-11-07 | Pasteur Institut | Nouveau procede de preparation d' alpha-glycosylceramides, nouveaux derives alpha-glycosylceramide et leurs applications |
EP1549323A2 (en) * | 2002-05-07 | 2005-07-06 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
US20050215487A1 (en) * | 2002-06-27 | 2005-09-29 | Holick Michael F | Conjugates comprising an nsaid and a sugar and uses thereof |
CN107434814B (zh) * | 2017-07-14 | 2019-05-03 | 中国科学院化学研究所 | 改性共轭聚合物及其制备方法和应用 |
KR102503769B1 (ko) * | 2020-07-10 | 2023-02-27 | 솔루스바이오텍 주식회사 | 측쇄 지방산을 포함하는 신규한 스핑고지질과 그의 용도 |
CN115260091A (zh) * | 2022-08-05 | 2022-11-01 | 深圳市迪克曼生物科技有限公司 | 含环状羧酸的神经酰胺类化合物及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH349592A (de) * | 1956-06-06 | 1960-10-31 | Ciba Geigy | Verfahren zur Herstellung von ungesättigten, aliphatischen Aminodiolen |
BE569345A (ko) * | 1957-07-12 | |||
GB1064293A (en) * | 1963-07-15 | 1967-04-05 | Bellon Labor Sa Roger | Substituted 2-pyrrylketones |
US3418325A (en) * | 1965-12-23 | 1968-12-24 | Bofors Ab | Method of producing a product between meso-inositol and nicotinic acid |
US3901893A (en) * | 1970-05-18 | 1975-08-26 | Richter Gedeon Vegyeszet | New dihydro-lysergic acid derivative |
HU169073B (ko) * | 1974-05-28 | 1976-09-28 | ||
US4064249A (en) * | 1974-05-28 | 1977-12-20 | Richter Gedeon Vegyeszeti Gyar Rt. | Compounds with ergoline skeleton |
DE2629135A1 (de) * | 1976-06-29 | 1978-01-12 | Nattermann A & Cie | Neue phospholipid-derivate von prostaglandinen und verfahren zu ihrer herstellung |
JPS565491A (en) * | 1979-06-19 | 1981-01-20 | Nattermann A & Cie | Nnoleyl derivative of phosphatidylethanolamine* its manufacture and medicine containing same for lipemia and arteriosclerosis |
IT1171432B (it) * | 1981-08-03 | 1987-06-10 | Fidia Farmaceutici | Amidi organiche derivate da lipidi azotati utilizzabili come farmaci |
-
1981
- 1981-08-03 IT IT49031/81A patent/IT1171432B/it active
-
1982
- 1982-07-26 GR GR68869A patent/GR76234B/el unknown
- 1982-07-27 DE DE8282401384T patent/DE3273983D1/de not_active Expired
- 1982-07-27 EP EP82401384A patent/EP0072286B2/en not_active Expired - Lifetime
- 1982-07-27 AT AT82401384T patent/ATE23165T1/de not_active IP Right Cessation
- 1982-07-30 NZ NZ201439A patent/NZ201439A/en unknown
- 1982-07-30 FI FI822672A patent/FI75829C/fi not_active IP Right Cessation
- 1982-08-02 PT PT75363A patent/PT75363B/pt not_active IP Right Cessation
- 1982-08-02 NO NO822631A patent/NO161314C/no unknown
- 1982-08-02 IL IL66454A patent/IL66454A0/xx not_active IP Right Cessation
- 1982-08-02 DK DK346282A patent/DK159204C/da not_active IP Right Cessation
- 1982-08-03 JP JP57136205A patent/JPS5843942A/ja active Granted
- 1982-08-03 KR KR8203484A patent/KR880000042B1/ko active
- 1982-08-03 ES ES514683A patent/ES8501735A1/es not_active Expired
- 1982-08-03 HU HU822492A patent/HU192771B/hu not_active IP Right Cessation
- 1982-08-03 ES ES533004A patent/ES8602616A1/es not_active Expired
- 1982-08-03 YU YU1689/82A patent/YU43085B/xx unknown
- 1982-08-03 AU AU86726/82A patent/AU561811B2/en not_active Ceased
- 1982-08-03 IE IE1863/82A patent/IE53644B1/en not_active IP Right Cessation
- 1982-08-03 ZA ZA825585A patent/ZA825585B/xx unknown
- 1982-08-03 PL PL1982237756A patent/PL141417B1/pl unknown
-
1985
- 1985-04-30 YU YU734/85A patent/YU42913B/xx unknown
- 1985-04-30 YU YU735/85A patent/YU42914B/xx unknown
- 1985-07-16 ES ES545241A patent/ES8608480A1/es not_active Expired
- 1985-12-11 US US06/807,841 patent/US4757053A/en not_active Expired - Fee Related
-
1988
- 1988-06-21 US US07/209,565 patent/US4897382A/en not_active Expired - Fee Related
- 1988-06-21 US US07/209,490 patent/US4897381A/en not_active Expired - Fee Related
-
1992
- 1992-01-09 JP JP4002254A patent/JPH0558976A/ja active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100496566B1 (ko) * | 2002-06-11 | 2005-06-23 | 주식회사 포스코 | 탈황능이 향상된 무연탄을 이용한 용선용 탈황제 |
US20190289401A1 (en) * | 2018-03-15 | 2019-09-19 | Onkyo Corporation | Diaphragm, speaker unit using same, headphone and earphone, and diaphragm manufacturing method |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR840001170A (ko) | 신규 유기아마이드 화합물의 제법 | |
KR880701726A (ko) | 1-히드록시-3-(n-메틸-n-프로필아미노)-프로판-1,1-디포스폰산 : 이들의 제법 및 이들을 함유하는 약제 | |
KR890011601A (ko) | (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약 | |
IE821846L (en) | Carbamimidoyl-1-carbadethiapen-2-em-3 carboxylic acid | |
DE3062609D1 (en) | Muramyldipeptide derivatives, process for preparing said compounds and pharmaceutical compositions containing said compounds | |
SU1279526A1 (ru) | "cпocoб пoлучehия пpoизboдhыx okcиmob пиpobиhoгpaдhoй kиcлotы или ee amидob" | |
KR840005733A (ko) | 무라밀 펩타이드의 제조방법 | |
KR880011139A (ko) | 크로몬 유도체 | |
DE3664212D1 (en) | Process for preparing l-homoalanin-4-yl(methyl)-phosphinic acids, as well as their alkyl esters | |
ATE124687T1 (de) | Verfahren zur herstellung von chinolincarbonsäuren. | |
SE8406554L (sv) | Nya gonadoliberinderivat och forfarande for deras framstellning | |
KR850008157A (ko) | 아미노산 및 이 에스테르의 n-아실유도체의 제조방법 | |
KR930004248A (ko) | α-아미노산, 그의 아미노산 에스테르 및 아미노산 아미드를 제조하는 방법 | |
KR890006620A (ko) | 퀴놀린 유도체 및 그의 제조법 | |
AU549272B2 (en) | Insulin b30 amino acid interchange using carboxypeptidase | |
ATE61369T1 (de) | Verfahren zur herstellung von oximosilanen. | |
ES524924A0 (es) | Procedimiento para preparar derivados de aminoacidos o diaminoacidos | |
KR840000530A (ko) | 신규 벤조트리아졸의 제조방법 | |
KR880011136A (ko) | 아졸- 아미노메틸렌 비스포스폰산 유도체 | |
WO1999044986A1 (en) | Acylated aminoacids for increasing the uptake of selected substances by organisms | |
KR830008489A (ko) | N-아실 아미노산 유도체의 제조방법 | |
EP0971899A4 (en) | HEXAHYDROINDENOPYRIDINE COMPOUNDS WITH ANTISPERMATOGENIC ACTIVITY | |
ATE77091T1 (de) | Verfahren zur herstellung von alphaaminoalkylphosphons|uren. | |
KR960003730A (ko) | 항-염증성 또는 무통활성을 가지는 조성물의 인산화된 유도체와 이의 준비방법 | |
JPS57142926A (en) | Preparation of difluoroethene derivative |